BioCentury | Jun 14, 2018
Translation in Brief

There’s more to MIF

...the pro-inflammatory MIF/CXCR2 and MIF/CXCR4 interactions while sparing tissue-protective ones, such as MIF/CD74. He said Carolus Therapeutics Inc....
BioCentury | Sep 2, 2013
Company News

Carolus, Alpha-1 Foundation deal

...in Carolus, but the partners are not disclosing terms of the deal or the investment. Carolus'...
...partners want to also evaluate if CT-2009 can modulate levels of the heterodimer in patients. Carolus Therapeutics Inc....
BioCentury | Mar 11, 2013
Financial News

Carolus completes venture financing

Carolus Therapeutics Inc. , San Diego, Calif. Business: Inflammation, Pulmonary, Autoimmune Date completed: 3/5/13 Type: Venture financing Raised: $2.3 million Investor: Square 1 Bank WIR Staff autoimmune Inflammation Pulmonary...
BioCentury | Oct 1, 2012
Emerging Company Profile

Innovimmune: Structuring immunotherapies

...allosteric and receptor pharmacophoric sites and therefore offer more complete functional inhibition of the target. Carolus Therapeutics Inc....
...on its small molecule portfolio. Companies and Institutions Mentioned Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Carolus Therapeutics Inc....
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication: Pulmonary disease

...edema in the lung compared with injection of an inactive control peptide. Ongoing work from Carolus Therapeutics Inc....
...injury. SciBX 5(5); doi:10.1038/scibx.2012.134 Published online Feb. 2, 2012 Patented by Aachen University; licensed to Carolus...
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication

...edema in the lung compared with injection of an inactive control peptide. Ongoing work from Carolus Therapeutics Inc....
...injury. SciBX 5(5); doi:10.1038/scibx.2012.134 Published online Feb. 2, 2012 Patented by Aachen University; licensed to Carolus...
BioCentury | Jan 30, 2012
Clinical News

Carolus preclinical data

...tissue damage. Data were published in the American Journal of Respiratory and Critical Care Medicine. Carolus...
...plans to submit an IND for the peptide antagonist of the CCL5-CXCL4 heterodimer in 3Q12. Carolus Therapeutics Inc....
BioCentury | Jun 9, 2011
Targets & Mechanisms

Short-circuiting DCs in atherosclerosis

...a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc....
...Christian Weber, director of the Institute for Cardiovascular Prevention at Aachen University and cofounder of Carolus...
...also in other vascular and pulmonary diseases," said Court Turner, president, CEO and director of Carolus...
BioCentury | Aug 2, 2010
Emerging Company Profile

Carolus: Targeting cytokines

...restrict the defensive functions of the immune system and increase a patient's susceptibility to infection. Carolus Therapeutics Inc....
...block specific cytokine interactions, leaving the other functions of the cytokines and their receptors intact. Carolus'...
...Companies and Institutions Mentioned Aachen University , Aachen, Germany Carolus Therapeutics Inc. , San Diego, Calif. Sidebars Carolus Therapeutics Inc....
BioCentury | Jan 22, 2009
Cover Story

Disrupting atherosclerosis

...disrupting interactions between two platelet-derived chemokines. 1 The findings have led to the formation of Carolus Therapeutics Inc....
...which put up the seed capital last year to help Weber and colleagues found Carolus...
...to potentially reducing inflammation at the vessel wall," said Joshua Schultz, VP of research at Carolus...
Items per page:
1 - 10 of 12
BioCentury | Jun 14, 2018
Translation in Brief

There’s more to MIF

...the pro-inflammatory MIF/CXCR2 and MIF/CXCR4 interactions while sparing tissue-protective ones, such as MIF/CD74. He said Carolus Therapeutics Inc....
BioCentury | Sep 2, 2013
Company News

Carolus, Alpha-1 Foundation deal

...in Carolus, but the partners are not disclosing terms of the deal or the investment. Carolus'...
...partners want to also evaluate if CT-2009 can modulate levels of the heterodimer in patients. Carolus Therapeutics Inc....
BioCentury | Mar 11, 2013
Financial News

Carolus completes venture financing

Carolus Therapeutics Inc. , San Diego, Calif. Business: Inflammation, Pulmonary, Autoimmune Date completed: 3/5/13 Type: Venture financing Raised: $2.3 million Investor: Square 1 Bank WIR Staff autoimmune Inflammation Pulmonary...
BioCentury | Oct 1, 2012
Emerging Company Profile

Innovimmune: Structuring immunotherapies

...allosteric and receptor pharmacophoric sites and therefore offer more complete functional inhibition of the target. Carolus Therapeutics Inc....
...on its small molecule portfolio. Companies and Institutions Mentioned Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Carolus Therapeutics Inc....
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication: Pulmonary disease

...edema in the lung compared with injection of an inactive control peptide. Ongoing work from Carolus Therapeutics Inc....
...injury. SciBX 5(5); doi:10.1038/scibx.2012.134 Published online Feb. 2, 2012 Patented by Aachen University; licensed to Carolus...
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication

...edema in the lung compared with injection of an inactive control peptide. Ongoing work from Carolus Therapeutics Inc....
...injury. SciBX 5(5); doi:10.1038/scibx.2012.134 Published online Feb. 2, 2012 Patented by Aachen University; licensed to Carolus...
BioCentury | Jan 30, 2012
Clinical News

Carolus preclinical data

...tissue damage. Data were published in the American Journal of Respiratory and Critical Care Medicine. Carolus...
...plans to submit an IND for the peptide antagonist of the CCL5-CXCL4 heterodimer in 3Q12. Carolus Therapeutics Inc....
BioCentury | Jun 9, 2011
Targets & Mechanisms

Short-circuiting DCs in atherosclerosis

...a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc....
...Christian Weber, director of the Institute for Cardiovascular Prevention at Aachen University and cofounder of Carolus...
...also in other vascular and pulmonary diseases," said Court Turner, president, CEO and director of Carolus...
BioCentury | Aug 2, 2010
Emerging Company Profile

Carolus: Targeting cytokines

...restrict the defensive functions of the immune system and increase a patient's susceptibility to infection. Carolus Therapeutics Inc....
...block specific cytokine interactions, leaving the other functions of the cytokines and their receptors intact. Carolus'...
...Companies and Institutions Mentioned Aachen University , Aachen, Germany Carolus Therapeutics Inc. , San Diego, Calif. Sidebars Carolus Therapeutics Inc....
BioCentury | Jan 22, 2009
Cover Story

Disrupting atherosclerosis

...disrupting interactions between two platelet-derived chemokines. 1 The findings have led to the formation of Carolus Therapeutics Inc....
...which put up the seed capital last year to help Weber and colleagues found Carolus...
...to potentially reducing inflammation at the vessel wall," said Joshua Schultz, VP of research at Carolus...
Items per page:
1 - 10 of 12